Shareholders Letter & Information Shareholder Letters Shareholders Letter, October 2019 Update on Corporate Governance, September 2019 Shareholders Letter, July 2019 Shareholders Letter, October 2017 Shareholders Letter, December 2016 Information GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT: Enhances Board of Directors with Two Strategic Appointments GENFIT: June 30, 2020 Annual Shareholders Meeting results GENFIT: Information relating to the shareholders meeting of June 11, 2020 GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis GENFIT: Updates to 2020 Financial Calendar GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic GENFIT Answers Investors’ Questions Raised Today - January 23, 2020 Information note – GENFIT: Cymabay Phase 2 data: read-across for RESOLVE-IT? – June 11, 2019 GENFIT: Clarification of Erroneous Trading Information (update Dec 21, 2018 – 08:30 pm CET), December 2018 2020.02.20 GENFIT PR - FDA 2020.02.20 GENFIT CP - FDA
GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis
GENFIT: Clarification of Erroneous Trading Information (update Dec 21, 2018 – 08:30 pm CET), December 2018
